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Abstract 
 
Over the past few decades a variety of biomolecules have been 
proposed as diagnostic biomarkers and predictors of severity for 
transmissible and nontransmissible diseases. Studies in a range of 
cancers have revealed many biomarkers with great potential in 
cancer diagnosis, in establishing tumor stage, progression, and 
response to therapies; such as the Kallikrein and 
Metalloproteinase families. Traditionally blood (serum) and tissue 
have been the main biological sources of biomarker discovery, but 
in the past decade urine has emerged as a promising source of 
cancer biomarkers. In this review we will focus on two large 
families, the Kallikrein family of serine proteases discovered in 
serum, and the Metalloproteinase family of zinc proteases 
discovered in urine, as potential cancer biomarkers. 
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Resumen 
 
Durante las últimas décadas una gran variedad de 
biomoléculas han sido propuestas como biomarcadores de 
diagnóstico y de predicción de severidad de enfermedades 
transmisibles y no transmisibles. Estudios realizados en variedad 
de cánceres han revelado muchos biomarcadores, como las familias 
Kalikreina y Metaloproteinasas, con gran potencial en el 
diagnóstico de cáncer, en el establecimiento del grado de cáncer, su 
progresión y su respuesta a las terapias. Tradicionalmente la 
sangre (suero) y tejido han sido las principales fuentes biológicas 
para el descubrimiento de biomarcadores, pero en la última década 
ha surgido la orina como fuente prometedora de biomarcadores de 
cáncer. Esta revisión se centra en dos grandes familias, la familia 
Kalikreina de las serina proteasas, descubiertas en suero, y la 
familia Metaloproteinasas de las zinc proteasas, descubiertas en la 
orina; las cuales son biomarcadores potenciales contra el cáncer. 
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1. INTRODUCTION 
 
Biomarkers are molecules whose levels of expression or 
modifications in the body are indicative of a biological state. These 
biomarkers can be genetic, epigenetic, proteomic or glycomic, and 
have great potential in cancer diagnosis, in establishing tumor 
stage, progression, and response to therapies. Improved 
understanding of cancer pathogenesis and the development of 
advanced techniques has revealed a large number of potential 
tumor markers, such as the Kallikrein and Metalloproteinase 
families. 
DNA, RNA and protein biomarkers are the most commonly 
studied. Traditionally, blood has been used as the primary 
biological sample for the discovery of biomarkers (Omenn, 2004); 
its biggest advantage being that it is in contact with all the cells in 
the body. However, using blood for proteomic analysis also has 
several disadvantages, such as the inevitable activation of 
proteases during sample collection, which generate an array of 
proteolytic products and thus introduce variability to the sample 
(Omenn et al., 2005). Additionally, blood has 20 high abundance 
proteins corresponding to 99% of the total protein (Veenstra et al., 
2005), which mask the other less abundant proteins during 
proteomic analysis. Due to these issues urine has emerged as a 
potential source of biomarkers. The Human Proteome 
Organization (HUPO) announced in October 2005 the inclusion of 
the Human Kidney and Urine Proteome Project 
(http://hkupp.kir.jp/) as one of their projects sanctioned under the 
Disease Biomarker Initiative (DBI). In contrast to blood, urine 
collection is minimally invasive, sample handling is simple and it 
has been shown that urine samples are particularly stable 
(Schaub, et al., 2004; Theodorescu et al., 2006) which significantly 
reduces variability. The main disadvantage of urine is the 
variation in protein concentration due to differences in fluid intake 
during the day, but this is controlled through protein 
standardization to creatinine in the sample (Vestergaard & 
Leverett, 1958). 
Thus, along with blood, urine has emerged as a promising 
biological source not only for the discovery of biomarkers of 
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diseases of the genitourinary tract (urological cancers, prostate 
cancer, etc.), but also of diseases affecting other organs of the body 
(brain tumors, breast cancer, and others). The first study on 
biomarkers in urine identified markers of brain tumors, breast, 
ovarian and bladder cancer (Moses et al., 1998). Most of these 
biomarkers were angiogenic factors (promote the formation of new 
blood vessels) belonging to the matrix metalloproteinase family 
(MMP). 
Another protease family which is found in serum of cancer 
patients and widely researched is the Kallikrein family. Initially it 
was thought there were only 3 members in this family (Riegman 
et al., 1992), but from 1995 onwards extensive work by several 
research groups has revealed a total of 15 members in the human 
kallikrein gene family. In this review we will focus on these two 
protease families, the kallikrein family of serine proteases found 
in blood, and the metalloproteinase family of zinc proteases found 
in urine; both potential biomarkers in cancer diagnosis and 
progression. 
 
 
2. KALLIKREIN FAMILY: SERINE PROTEASES 
 
2.1 Characteristics 
 
The kallikrein family is a group of proteins with enzymatic 
activity. Initially, only three kallikrein proteins were identified 
(classic hK): pancreatic-renal kallikrein (hK1) was first 
characterized in the 1930s, followed by prostate kallikrein (hK3) 
which was discovered from several independent studies in the 60s 
(Yousef & Diamandis, 2001). The Kallikrein family was finally 
defined as such due to the subsequent characterization of a 
protein called human glandular kallikrein (hK2) (Enami & 
Diamandis, 2008). Studies in the 90s, led to the identification of 
new family members, due to the high homology observed with the 
classical kallikreins at both the genomic and structural level 
(Yousef & Diamandis, 2001). There are currently 15 proteins with 
serine-protease activity in this family, mentioned in Table 1. 
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Table 1. Kallikrein Family Members 
Gene/Protein Disease References 
KLK1 / hK1 
Sepsis, pancreatic disease, 
cancer 
Yousef & Diamandis, 
2001 
KLK2 / hK2 Breast and prostate cancer Partin et al., 1999 
KLK3 / hK3 Breast and prostate cancer 
Poliouras & 
Diamandis, 2006 
KLK4 / hK4 Ovarian cancer Prezas et al., 2006 
KLK5 / hK5 Ovarian cancer Dong et al., 2003 
KLK6 / hK6 
Ovarian and breast cancer, 
Alzheimer’s disease 
Pampalakis & 
Sotiropoulou, 2006 
KLK7 / hK7 
Ovarian cancer, psoriasis, 
keratinization 
Dong et al., 2003 
KLK8 / hK8 
Ovarian cancer, Kindling 
epilepsy 
Magklara et al., 2001 
KLK9 / hK9 Ovarian cancer Yousef et al., 2001 
KLK10 / hK10 Breast and prostate cancer 
Sidiropoulos et al., 
2005 
KLK11 / hK11 Ovarian and prostate cancer Luo et al., 2006 
KLK12 / hK12 Breast cancer Borgoño et al., 2004 
KLK13 / hK13 Breast cancer Chang et al., 2001 
KLK14 / hK14 Breast cancer 
Poliouras & 
Diamandis, 2006 
KLK15 / hK15 Prostate cancer Borgoño et al., 2004 
 
The KLK genes are flanked by noncoding regions at both the 5' 
and 3' ends (NTR5' and NTR3', Non-translated region) (Fig. 1). 
There can be two NTR regions at the 5' end, whereas only one 
NTR has been characterized in the 3' end (Kurlender et al., 2004). 
These genes contain five exons (designated from 1 to 5), which are 
highly conserved in all 15 KLK family members (Fig. 1). A pattern 
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of alternating intron regions of variable size, designated 0, I, II 
and III, can be observed between exons (Yousef & Diamandis, 
2001). Generally, the initiation codon (AUG) is located 8-87 base 
pairs downstream of exon 1, while the stop codon is located 
between nucleotides 150-189 after the start of the coding segment 
of exon 5 (Pampalakis & Sotiropoulou, 2007). 
 
 
Fig. 1. Structural features of a conserved Kallikrein gene H, D and S correspond to 
the catalytic histidine, aspartic acid and serine residues located in the active site. 
Black boxes (1 to 5) indicate coding sequences. Gray boxes represent introns (0 to 
III). Kallikrein genes are flanked by non-coding regions at 5’ and 3’ termini, 
Start codon.  Stop codon. 
 
hK proteins synthesized from KLK genes, are single-chain 
peptides secreted as preproenzymes. As shown in Fig. 1, each hK 
contains a 16-30 amino acid signal peptide in the N-terminus, 
followed by a 4-9 amino acid pro-peptide and a catalytic domain 
that is activated by successive post-translational cleavages during 
its maturation stage in the secretory pathway (Yousef & 
Diamandis, 2001). Generally, mature and catalytically active hK 
proteins are 227-252 amino acids long with approximately 10 to 12 
cysteine residues which are important in the formation of disulfide 
bonds, and consequently for the tertiary structure; and have a 
highly conserved catalytic triad containing histidine (H), aspartic 
acid (D) and serine (S) residues (Gomis-Ruth et al., 2002). 
 
2.2 Utility of Kallikreins in Biomedical Research 
 
Biochemical studies have determined that kallikreins are 
differentially expressed in human tissues, fluids and organs, 
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enabling their use as biomarkers (Yousef & Diamandis, 2001). 
Differential transcription of messenger RNA (mRNA) and/or 
protein expression has been observed in: central nervous system, 
thyroid, prostate, seminal fluid, testis, ovary, uterus, colon, skin, 
heart, breast, lung and trachea (Shaw & Diamandis, 2007), and 
changes in these kallikreins have been described in several 
pathological processes such as inflammation, hypertension, kidney 
disease, pancreatitis and cancer, among others (Table 1). 
 
2.2.1 Prostate cancer biomarkers 
 
Prostate cancer is the second most common cancer in 
Colombian men, with an estimated annual mortality rate of 2.885 
men (According to the GLOBOCAN 2002 database). Currently, 
diagnosis is based on serum measurements of prostate specific 
antigen (PSA, hK3), and a digital rectal examination of the 
prostate. 
hK3, more commonly known as PSA, functions normally 
within the prostate to liquefy seminal coagulum, however it tends 
to be upregulated in prostate cancer. Although hK3 concentration 
is generally higher in serum of patients with prostate cancer, its 
expression is negatively regulated within the tumor tissue, which 
is associated with a more aggressive diagnosis (Magklara et al., 
2000); hence hK3 has been associated with tumor suppressor 
activity, pro-apoptosis and negative regulation of cell growth 
(Diamandis, 2000). hK3 serves not only as a biomarker in cancer 
diagnosis, but also as a predictor of severity and progression. 
Protein hK2 is similar to hK3 (PSA). According to some 
immunohistochemical studies, hK2 is expressed in higher levels in 
prostate tumor tissue than in hyperplastic prostate tissue or 
normal tissue, however other quantitative studies have reported a 
similar expression trend to hK3 (Finlay et al., 1998; Magklara et 
al., 2000). In addition to KLK2 and KLK3, other kallikrein family 
members, such as KLK5, 6, 10 and 13, are found to be negatively 
regulated at the transcriptional level in tumor tissue of patients 
with prostate cancer when compared with surrounding normal 
tissue (Hakalahti et al., 1993; Petraki et al., 2003; Sotiropoulou et 
al., 2003). 
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2.2.2 Endocrine cancer biomarkers 
 
Serine protease hK5 is secreted mainly by skin, testes, brain 
and mammary gland tissue and presents a high proteolytic 
activity (Shaw & Diamandis, 2007). Transcription of KLK5 mRNA 
is positively regulated by steroid hormones; this has been verified 
in a human breast tumor cell line (BT-474) and has led to the 
exploration of mRNA over-expression in endocrine malignancies, 
revealing an increase of this biomarker in breast, testicular and 
ovarian cancers (Yousef et al., 2004). 
In general, upregulation of mRNA or protein has been 
observed in kallikreins 4, 5, 6, 7, 8, 10, 11, 12, 13, 14 and 15, both 
in tissue and serum of patients with ovarian cancer (Table 1). In 
contrast, mRNA synthesis of kallikreins 3, 10, 12, 13 and 14, was 
found to be reduced in breast tumor tissue and cell lines derived 
from breast cancer (Yousef & Diamandis 1999; 2001; Dhar et al., 
2001); although KLK6 mRNA is upregulated in primary breast 
cancer tissue, it is transcribed at a reduced rate in metastatic 
breast cancer (Anisowicz et al., 1996). In particular, transcription 
of KLK5 and KLK14 is decreased in breast cancer, although in 
some patients it is possible to detect elevated levels of proteins 
hK5 and hK14 in serum (Borgoño et al., 2006). This increased rate 
of hK synthesis can be explained by glandular destruction 
processes or angiogenesis, which are common events in the 
development of neuroendocrine tumors and may increase the level 
of hK proteins in the intravascular compartment. 
 Increased mRNA levels of KLK5, KLK10 and KLK14 have 
been reported in patients with testicular cancer when compared to 
healthy individuals (Luo et al., 2003), and transient transfection of 
the KLK10 gene in breast cancer derived cell lines decreased the 
anchorage independent growth of these cells and their ability to 
form tumors (Roman-Gomez et al., 2004). These kinds of results 
have led to the conclusion that KLK10 is a tumor suppressor gene. 
These kallikrein biomarkers are not only useful in cancer 
diagnosis, but are also serological markers of prognosis. For 
example, finding high mRNA or protein levels of kallikreins 4, 5, 
6, 7, 10 and 15 is considered a poor prognosis for the patient, given 
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that studies have shown a more severe clinical outcome and lower 
rates of survival in these patients (Preza et al., 2006; Enami & 
Diamandis 2008). By contrast, kallikreins 8, 9, 11 and 14 are 
markers of good prognosis; high concentrations of these markers 
are associated with higher rates of survival and recovery from 
illness (Borgoño et al., 2004). 
 
 
3. METALLOPROTEINASES: ZINC PROTEASES 
 
3.1 Metalloproteinase Superfamily 
 
The metalloproteinase superfamily encodes a highly conserved 
zinc-binding motif containing three histidine residues which bind 
zinc in the active site. This superfamily includes matrix 
metalloproteinases (MMPs) and ADAMs (a disintegrin and 
metalloproteinase) (Stöcker et al. 1995). 
The MMP family has 28 closely conserved members. Most 
MMPs share a common structure, composed of a pro-peptide 
domain, a catalytic domain, a hinge region, and a hemopexin-like 
domain (Fig. 2). At least 15 members are Zn-dependent; their 
activity relies on a Zn2+ metal ion bound within the catalytic 
domain in the conserved HExxHxxGxxH sequence (Fig. 2). The 
pro-peptide domain can bind to the Zn ion in the catalytic domain 
keeping the enzyme inactive, while the hemopexin-like domain is 
thought to be involved in protein-protein interactions, which helps 
determine substrate specificity. MMPs are synthesized as pro-
enzymes and most are secreted before being converted to their 
active form; in order to be activated the pro-domain must be 
cleaved from the catalytic domain. A signal peptide at the N-
terminus targets these proteins for the secretory pathway and is 
removed prior to secretion from the cell. Although most MMPs are 
secreted proteins, integral membrane MMPs have also been 
described (MT-MMPs), anchored to the cell membrane by a 
transmembrane and intracytoplasmic domain (Jones et al., 2003). 
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Fig. 2. Structural domains of the MMP and ADAM families. The structures shown 
in this figure describe the majority of MMP and ADAM family members 
 
The main role of these human zinc proteases is in tissue 
remodeling. This function is exploited by tumor cells which use 
MMPs to break down components of the extracellular matrix, thus 
allowing malignant cell migration to other parts of the body 
(metastasis) (Fig. 3). Leukocytes that are involved in 
inflammatory processes are the main source of MMPs (Fig. 3). 
The ADAM family (a disintegrin and metalloproteinase) is 
closely related to the MMP family as they are also zinc 
metalloproteinases and have an extracellular metalloproteinase 
domain (Fig. 2). ADAM proteins possess a prodomain, 
metalloproteinase, disintegrin, cysteine rich, EGF, 
transmembrane and cytoplasmic domains (Fig. 2). The 
metalloproteinase domain is similar to that found in MMPs and 
contains the same zinc-binding site. The disintegrin domain binds 
integrin and inhibits platelet aggregation. The cystein rich and 
EGF domain have many cystein residues which form disulfide 
bonds; however, the function of these domains is not yet well 
understood. Most ADAMs are integral membrane proteins, 
anchored with a C-terminus transmembrane domain and 
containing a cytosolic domain which is involved in signalling; but 
some members of the ADAM family are cleaved and targeted to 
the secretory pathway. 
These proteins play a role in cell-cell and cell-matrix 
interactions, and in recent years evidence has emerged of ADAM 
proteins in tumor tissues, acting specifically in angiogenesis and 
metastasis processes (Lu et al., 2008) (Fig. 3). 
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Fig. 3. Role of MMPs and ADAMs in cancer pathogenesis. MMPs and ADAMs 
modulate the tumor microenvironment by increasing the availability of pro-
angiogenic factors like VEGF, thus promoting the formation of new blood vessels 
that feed the tumor. They also degrade the components of the basal membrane and 
extracellular matrix, facilitating the migration of cancer cells to other parts of the 
body 
 
3.2 Utility of MMPs in Biomedical Research 
 
3.2.1 Brain tumor biomarkers 
 
The incidence of metastatic brain tumors is on the rise (Barker 
et al., 2005). The main problem in treating brain tumors is the 
lack of diagnostic tools to detect this disease. Two contemporary 
studies in 1998 addressed this issue by reporting the presence of 
enzymes in brain tumors (Surawicz et al., 1998) and in urine 
samples taken of these patients (Moses et al., 1998). Based on 
these publications a more detailed study was initiated in 2008 to 
examine the effectiveness of these proteins as potential 
noninvasive biomarkers of brain tumors (Smith et al., 2008). 
A study with patients with a variety of brain tumors led to the 
discovery of metalloproteinases MMP-2, MMP-9, MMP-9/NGAL 
and VEGF (vascular endothelial growth factor) in urine samples 
collected at random, whereas these were not found in urine 
samples of the healthy control group (Smith et al., 2008). The 
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expression patterns of these molecules found in urine reflect the 
expression patterns in brain tissue; patients with decreased MMP-
2 activity in urine also had low MMP-2 levels of expression in the 
tumor tissue, while patients with high MMP-9 activity in urine 
retained elevated levels of MMP-9 in the tumor. Additionally it 
was shown that elevated levels of these biomarkers in urine 
decreased after effective surgical treatment of the tumor. It is 
important to note that in serum elevated levels of MMP-9 have 
also been detected, in patients with colorectal cancer (Wilson et 
al., 2006), breast cancer (Quaranta et al., 2007) and ovarian cancer 
(Lin et al. , 2009). 
As shown in Fig. 3, this family of metalloproteinases modulate 
the tumor microenvironment in several ways: a) Encouraging 
tumor growth by releasing insulin-like growth factor IGF. b) 
Promoting the formation of new blood vessels (angiogenesis) that 
feed the tumor, by increasing the availability of pro-angiogenic 
factors like VEGF. c) Facilitating the migration of cancer cells 
(metastasis) by degrading the extracellular matrix components. In 
particular two members of this family, MMP-2 and MMP-9, 
degrade collagen, fibronectin and laminin, which are major 
components of the basal membrane. 
 
3.2.2 Brest cancer biomarkers 
 
Breast cancer remains the most common cancer among women 
and the second leading cause of death by cancer (Parkin & 
Fernandez, 2006). The priority is to identify women at high risk of 
developing breast cancer. 
Recently, interest in a protein called ADAM-12 as a potential 
biomarker of breast cancer has increased. Immunohistochemical 
studies of breast tumor tissue have demonstrated increased 
expression of ADAM-12 and MMPs (Iba et al., 1999), which have 
also been found in high levels in the urine of these patients 
(P<0.001) (Moses et al., 1998). A well-designed study showed that 
women with high levels of MMP-9 and ADAM-12 in urine are 5 
times more likely to develop atypical hyperplasia and 13 times 
more likely to develop lobular carcinoma in situ (Pories et al., 
2008), which are precursors of cancer. So, these biomarkers not 
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only act as indicators of the presence of breast cancer, but also as 
high risk predictors. It is reported that ADAM-12, expressed by 
cancer cells, accelerates breast cancer progression by inducing 
apoptosis of stromal cells (Kveiborg et al., 2005) and by degrading 
several extracellular matrix components such as collagen type IV 
and fibronectin (Roy et al., 2004). 
 
 
4. CONCLUSIONS 
 
The effectiveness of the Kallikrein and Metalloproteinase 
families as tools in cancer diagnosis, in monitoring progression, 
therapeutic success and recurrence of the disease, has been 
demonstrated. As can be seen from many of these studies, urine 
has emerged as an ideal non-invasive source of biomarkers; 
although it is a relatively recent area of work, it is one which is 
receiving much attention. 
In the future it will be necessary to develop panels of 
biomarkers, given that in many cases a diseased state cannot be 
effectively defined using a single biomarker. For example, high 
levels of MMP-9 were detected in the urine of patients with brain 
tumors, breast and prostate cancer, among others, so MMP-9 
could be used as an indicator of the existence of cancer, but would 
not indicate the type of cancer. A combination of general cancer 
biomarkers and specific biomarkers would be an optimal detection 
panel. 
 To date, of the biomarkers mentioned in this review, only hK3 
(PSA) has been clinically implemented as a biomarker (of prostate 
cancer). Along with the discovery of new biomarkers, the challenge 
now will be the validation of the existent biomarkers in a large 
study population, and their clinical implementation. 
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